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Graft-versus-host disease (GVHD) prophylaxis with post-transplantation cyclophosphamide (CY) after abla-
tive HLA-matched bone marrow (BM) transplantation has been reported to have comparable rates of acute
GVHD with an apparent reduction in chronic GVHD and infections when compared to historical prophylaxis
with a calcineurin-inhibitor (CNI) and methotrexate (MTX). We conducted a phase II trial of post-
transplantation CY (post-CY) after reduced-intensity conditioning (RIC) using intravenous busulfan (area
under the curve of 4000 micromolar minute), ﬂudarabine (40 mg/m2) for 4 days, and CY 50 mg/kg on daysþ3
and þ4 after BM or peripheral blood (PB) transplantations from matched related (MRD) or unrelated donors
(MUD). MUD recipients received antithymocyte globulin (ATG); however, a later amendment removed ATG.
Forty-nine patients were treated (acute myeloid leukemia/myelodysplastic syndrome, 82%). Median age was
62 years (range, 39 to 72). Fifteen patients received an MRD (9 PB/6 BM); 34 had a MUD (2 PB/32 BM). The
cumulative incidence of grade II to IV acute GVHD, III to IV acute GVHD, and chronic GVHD was 58%, 22%, and
18%, respectively. A matched cohort analysis compared outcomes to tacrolimus/methotrexate GVHD pro-
phylaxis and indicated higher rates of acute GVHD grade II to IV (46% versus 19%; hazard ratio [HR], 2.8; P ¼
.02) and treatment-related mortality (HR, 3.3; P ¼ .035) and worse overall survival (HR, 1.9; P ¼ .04) with post-
CY. The incidence of chronic GVHD and CMV reactivation did not differ. This study suggests that post-CY
should not be used as sole GVHD prophylaxis after a RIC transplantation from HLA-matched donors.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Graft-versus-host Disease (GVHD) remains a major limi-
tation to allogeneic hematopoietic cell transplantation [1]. A
calcineurin inhibitor (CNI), tacrolimus or cyclosporine,
combined with methotrexate (MTX) is the most common
GVHD prophylactic strategy; however, it is limited by toxic-
ities and the need for prolonged exposure to its immuno-
suppressive effects. Additionally, animal models suggest that
prolonged exposure to a CNI may paradoxically increase the
rate of chronic GVHD [2-5].edgments on page 911.
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ty for Blood and Marrow Transplantation.Recently, the use of post-transplantation cyclophospha-
mide (post-CY) given on days 3 and 4 after a matched donor
bone marrow (BM) transplantation has been evaluated as
an alternative regimen for preventing GVHD [6]. Cyclo-
phosphamide (CY) is administered in the early period after
allograft infusion to eliminate alloreactive T cell clones and
reduce GVHD. This regimen spares hematopoietic stem cells
and also T regulatory cells which express aldehyde dehy-
drogenase [7]. This approach avoids the need for additional
immunosuppressive agents [8]. In so doing, it is hypothe-
sized that it improves immune reconstitution and reduces
infections and chronic GVHD.
Luznik et al. published a prospective study using this
strategy wherein patients with hematologic malignancies
received an ablative conditioning regimen of busulfan (Bu)
and CY followed by a T cellereplete BM graft from a matched
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GVHD prophylaxis [6]. In this report, the incidence of grades
II to IV and III and IV acute GVHD were 43 and 10%, respec-
tively; rates comparable to CNI/MTX prophylaxis. Encour-
agingly, the rates of chronic GVHD and viral infections
appeared lowered than in historical reports. Similar results
were reported in a multicenter study using myeloablative
busulfan-ﬂudarabine conditioning [9].
We performed a prospective, phase II study to determine
if post-CY could be used as sole GVHD prophylaxis after a
reduced-intensity conditioning (RIC) regimen in a popula-
tion for whom ablative conditioning would be inappropriate
because of age or comorbidities. We found that, unlike the
experience with ablative conditioning, the rates of acute
GVHD and treatment-related mortality (TRM) were inferior
to that in matched historical controls receiving tacrolimus-
methotrexate GVHD prophylaxis.
METHODS
Study Design and Patients
This was a prospective single-center phase II trial to examine the safety
of RIC using intravenous Bu and ﬂudarabine (Flu) followed by post-CY as
sole GVHD prophylaxis in recipients of MRD or MUD transplantation for
hematologic malignancies. The trial was registered with clinicaltrials.gov
(NCT00800839) and approved by the institutional review board of the
University of Texas MD Anderson Cancer Center. All patients provided
written informed consent in accordance to the Declaration of Helsinki.
The primary endpoint was the incidence of grades II to IV acute GVHD.
Secondary endpoints included the rates of engraftment and chronic GVHD
and the probability of progression-free and overall survival (PFS and OS).
The method of Thall, Simon, and Estey was used for safety monitoring,
wherein stopping rules were based on historical rates for graft failure (GF,
lack of neutrophil engraftment by day 30), day 100 TRM (mortality not
attributable to relapse and without GF within the ﬁrst 100 days), and grade
III and IV acute GVHD by 100 days with historical baseline rates of 5%, 20%,
and 20%, respectively [10,11].
Patients between the ages of 6 months and 75 years with hematological
malignancies and a HLA-A, -B, -C, and -DR alleleematched related or un-
related donor were eligible. Eligible patients had to be deemed a poor
candidate for myeloablative conditioning because of age > 60 years, a
reduced performance status, prior transplantation, or impaired organ
function. Patients were required to have a total bilirubin  1.5 mg/dL and
transaminases less than 3 times the upper limits of normal, a creatinine
clearance above 50 mL/minute, a diffusing capacity for carbon monoxide >
45% predicted corrected for hemoglobin, and a left ventricular ejection
fraction of  35%. Patients with uncontrolled infections, human immuno-
deﬁciency virus seropositivity, or inability to provide informed consent or
assent were excluded.
Preparative Regimen and Supportive Care
A reduced-intensity preparative regimen of Bu and Flu was utilized as
has been reported by Popat et al. [12]. A similar regimen has been reported
by Mohty et al. in a large, multicenter, phase 2 trial [13]. A “test dose” of Bu,
32 mg/m2, was given on day -8 before transplantation. Based on the phar-
macokinetic data generated from the test dose, an adjusted dose of Bu was
administered at a dose calculated to achieve a systemic exposure of 4000
micromolar-minute. Patients received Flu 40 mg/m2 intravenously over 1
hour followed by Bu, infused over 3 hours, daily on days -6 to -3. Patients
received either a peripheral blood (PB) or BM graft on day 0 followed by CY
50 mg/kg intravenously on days þ3 and þ4. Mesna 10 mg/kg intravenous
piggy-back (IVPB) was given before the ﬁrst dose of CYand repeated every 4
hours for 10 doses. In patients for whom pharmacokinetic monitoring was
not feasible, Bu 100 mg/m2/day was administered for 4 days. Recipients of
MUDs received antithymocyte globulin (ATG) on days3 to1 (total dose of
4 mg/kg). ATG was included in the preparative regimen based on institu-
tional practice for recipients of unrelated donors and to allowmatching with
control patients receiving traditional prophylaxis. The protocol was amen-
ded removing ATG after the 34th enrolled patient to evaluate whether ATG
was negatively inﬂuencing outcomes as the original reports from Luznik
et al. did not include this agent [6].
Patients received antiseizure prophylaxis with phenytoin before the test
dose of Bu and continued until its completion. Granulocyte colonye-
stimulating factor (5 mg/kg/day) was given starting on dayþ5 and continued
until the absolute neutrophil count was greater than 500  109/L for 3
consecutive days. All supportive care measures were given per institutionalpractice and included routine antimicrobial prophylaxis against bacterial,
fungal, Pneumocystis jirovecii, and herpes simplex infections. Patients were
monitored weekly for cytomegalovirus (CMV) reactivation via CMV pp65
antigen testing or polymerase chain reaction with preemptive therapy
started in those with evidence of CMV reactivation.
Regimen-Related Toxicity and Diagnosis and Treatment of Acute GVHD
Toxicities were graded according to the National Cancer Institute criteria
(Common Toxicity Criteria version 3). Patients suspected of having acute
GVHD underwent histologic conﬁrmation; patients with clinical grade II or
higher GVHD were promptly started on systemic corticosteroids and a CNI.
Acute GVHD was graded according to the Modiﬁed Consensus Criteria,
whereas chronic GVHD was classiﬁed according to the National Institute of
Health’s guidelines [14,15].
Engraftment and Donor Chimerism
Neutrophil and platelet engraftment were deﬁned as the ﬁrst of 3
consecutive days with an absolute neutrophil count  .5  109/L and a
platelet count  20,000 without transfusion in the preceding 7 days,
respectively. Primary GF was deﬁned as a lack of neutrophil recovery not
attributable to recurrent marrowmalignancy. Secondary GFwas deﬁned as a
donor chimerism of < 5% not attributable to recurrent marrow malignancy
in a previously engrafted patient. Donor chimerismwas determined on days
30 and 100 after transplantation.
Statistical Analysis
The rates of GVHD and TRM were estimated from the date of trans-
plantation using the cumulative incidence method to account for competing
risks. Death or disease progression before diagnosis of GVHD were consid-
ered competing risks in the estimation of the incidence of GVHD; disease
progression or relapse death were considered competing risk for TRM. OS
and PFS were estimated using Kaplan-Meier method. Cox’s proportional
hazards regression analysis was used to assess the impact of the following
risk factors: patient age, diagnosis, donor type, disease status at time of
transplantation, sex and donor/recipient sex mismatch, and conditioning
regimens on primary and secondary endpoints. The impact of ATG was
examined separately for recipients of MUD and the impact of graft source
was only examined in MRD recipients as there were too few recipients of PB
in the MUD cohort. Statistical signiﬁcance was determined at the .05 level.
Statistical analyses were performed using STATA 11.0 (StataCorp. 2009. Stata
Statistical Software: Release 11. College Station, TX).
Matched Cohort Analysis Design
A computer-generated algorithm was used to identify a comparable
control group who received GVHD prophylaxis with tacrolimus and short-
course MTX (5 mg/m2 on days þ1, þ3, þ6, þ11) and a RIC transplantation
during the same time period. RIC consisted of the Bu/Flu regimen employed
in the trial patients or Flu (total dose of 125 mg/m2) in combination with
melphalan (total dose 140 mg/m2). Supportive care was otherwise identical.
Patients were identiﬁed from the departmental database matching in order
of priority for age, diagnosis (type of malignancy), disease status at trans-
plantation, donor type, graft source, and use of ATG.
RESULTS
Patient Characteristics
Forty-nine (49) patients were enrolled between
November 2008 and July 2011. Acute myeloid leukemia
(AML) and myelodysplastic syndrome were the most com-
mon indications for transplantation, occurring in 82% (40
patients) of the enrolled patients with 24% (12 patients) in
ﬁrst or second complete remission. The median age was 62
years (range, 39 to 72) with a median comorbidity index of 3
(range, 0 to 10). Fifteen patients received a transplantation
from a matched sibling, of which 9 had a PB graft and 6 had
BM, whereas the majority of the 34 MUD recipients received
BM (32 patients) (Table 1). The median follow-up for sur-
viving patients was 32 months (range, 24 to 43).
Engraftment
The median time to neutrophil engraftment was 16 and
20 days for recipients of PB and BM grafts, respectively,
whereas themedian time to platelet engraftment was 25 and
26 days, respectively. Stopping criteria were met when 5
Table 2
Outcomes for Post-CY after RIC for Patients with Hematologic Malignancies
(N ¼ 49)
Outcome % Cumulative
Incidence
95% CI
Acute GVHD grade II to IV at day 100 53% 40-70
Acute GVHD grade III to IV at day 100 22% 13-38
Chronic GVHD at 1 year 18% 9-33
Day 100 TRM 14% 7-28
1-year TRM 31% 20-47
CMV reactivation (patients at risk) 54% 40-72
Progression at 2 years
Overall 26% 17-42
AML in CR1 or CR2 18% 5-64
AML > CR2 31% 18-53
PFS at 2 years
Overall 26% 15-39
AML in CR1 or CR2 36% 11-63
AML > CR2 24% 11-40
OS at 2 years
Overall 33% 20-46
AML in CR1 or CR2 36% 11-63
AML > CR2 31% 16-48
Table 1
Patient Characteristics
Characteristic Post-CY All Enrolled Patients
n ¼ 49
Post-CY Matched Subset
n ¼ 37
Tacrolimus þ MTX Matched Control
n ¼ 37
P Value*
Male/female 28/21 21/16 22/15 .80
Age, median (range), yr 61 (39-72) 61 (39-72) 62 (37-72) .80
Comorbidity index, median (range) 3 (0-10) 3 (0-10) 3 (0-8) .40
Diagnosis (%)
AML/MDS 40 30 (81%) 30 (81%) 1.00
ALL 1 1 (3) 1 (3)
CLL 5 4 (11) 0 (0)
NHL 3 2 (5) 6 (16)
Stage at transplantation (%)
CR1 9 5 5 1.00
CR2 3 3 4
Primary induction failure 19 12 12
Untreated 3 3 4
>CR2 15 14 12
Donor and stem cell source
MRD BM 6 6 1 .04
MRD PB 9 9 14 .10
MUD BM 32 20 16
MUD PB 2 2 6
ATG (MUDs only) 22 22 22 1.00
RIC regimen
BU/Flu 49 37 15
Flu/Mel 22
Female D/male R 9 8 3 .09
CMV status D/R
Dþ or /Rþ 39 31 27 .30
Dþ/R 6 3 5
D/R 4 3 5
MDS indicates myelodysplastic syndrome; ALL, acute lymphocytic leukemia; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin lymphoma; CR, complete
remission; Mel, melphalan; D, donor; R, recipient.
* P value for comparison of Post-CY matched cohort and tacrolimusþMTX matched control.
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primary GF (6%) and 2 patients experienced delayed
engraftment. These rates are similar to GF rates seen in other
studies [9,16]. All 3 patients with primary GF received BM, 2
from MUDs and 1 from a sibling; none of these patients
received ATG. Two of these 3 patients died from infectious
complications, and the third patient is alive and in remission
after a second transplantation. The infused total nucleated
cell (TNC) dose did not differ between the 3 patients with
primary GF (median TNC/kg, 2.97  108) and engrafting
patients (median TNC/kg, 2.98  108) after BM infusions. Of
the 2 patients with delayed engraftment, both received BM
grafts from anMRD. One engrafted on dayþ38 but died from
infectious complications on day þ48 after transplantation;
the second patient engrafted on dayþ30. Themedian TNC/kg
was lower in these 2 patients (.73  108) when compared
with engrafted patients (2.98 108, P¼ .05). The median day
30 donor chimerism for evaluable engrafting patients was T
cell, 100% (range, 0 to 100) and myeloid, 100% (range, 0 to
100), and the median day 100 chimerism was T cell, 100%
(range, 0 to 100) and myeloid, 100% (range, 34 to 100). Mixed
T cell and myeloid chimerismwere present at 30 days in 28%
(n ¼ 13) of engrafting patients.
Acute and Chronic GVHD, TRM, and Survival
The cumulative incidence of day 100 grade II to IV and III
and IV acute GVHD was 53% (95% conﬁdence interval [CI],
40% to 70%) and 22% (95% CI, 13% to 38%), respectively. The
cumulative incidence of chronic GVHD at 1 year was 18%
(95% CI, 9% to 33%). The day 100 and 2-year TRM were 14%
(95% CI, 7% to 28%) and 39% (95% CI, 27% to 55%) (Table 2).
Risk factors analysis for the rate of acute GVHD and TRM
were assessed in 46 patients who engrafted. Patient age, sex,donor/recipient sex mismatch, diagnosis, disease status at
transplantation, and conditioning regimenwere found not to
impact the rate of acute GVHD II to IV and III and IV, OS,
progression, or TRM (Supplemental Table 1). The impact of
graft source on the rate of acute GVHD was examined in the
MRD cohort. Excluding patients with early deaths and
delayed engraftment, our data showed a higher incidence of
acute GVHD grade II to IV after receipt of PB; however, this
did not reach statistical signiﬁcance (56% versus 40%; hazard
ratio [HR], 1.1; P ¼ .90; 95% CI, .2 to 5.9) (Table 3). The impact
of ATGwas examined in the MUD BM cohort (n¼ 30 patients
Table 3
Cumulative Incidence of Grade II to IV and III to IV Acute GVHD at Day 100,
and 1-Year NRM in Matched Siblings who Received PB versus BM and
Matched Unrelated Donors Who Did or Did Not Receive ATG*
Outcome (N ¼ 44*) % Cumulative
Incidence
HR (95% CI) P Value
Acute GVHD II to IV
MRD PB (n ¼ 9) 56% (31-100) 1.1 (.2-5.9) .90
MRD BM (n ¼ 5) 40% (14-100) Ref.
Acute GVHD III to IV
MRD PB 11% (2-70) N/E .50
MRD BM 0%
Acute GVHD II to IV
MUD BM ATG (n ¼ 20) 36% (21-68) Ref. .03
MUD BM No ATG (n ¼ 10) 80% (59-100) 2.8 (1.1-7.5)
Acute GVHD III to IV
MUD BM ATG (n ¼ 20) 10% (3-41) Ref. .10
MUD BM No ATG (n ¼ 10) 50% (27-93) 3.1 (.8-11)
NRM 1-year
MUD BM ATG (n ¼ 20) 25% (12-53) .4 .25
MUD BM No ATG (n ¼ 10) 40% (19-85) Ref.
* Three patients who experienced primary graft failure were removed
from the analysis (2MUD BM recipients and 1MRD BM recipient). TwoMUD
patients who received PB and ATG were removed from the analysis of the
effect of ATG.
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acute GVHD grade II to IV was higher for those patients who
did not receive ATG (80% versus 36%; HR, 2.8; P ¼ .03; 95% CI,
1.1 to 7.5) (Table 3). There was a trend toward decreased 2-
year NRM in the ATG group (25% versus 40%; HR, .4)
though this was not statistically signiﬁcant (P¼ .25) (Table 3).
For the entire cohort, the 2-year PFS and OS probabilities
were 26% (95% CI, 15% to 39%) and 33% (95% CI, 20% to 46%),
respectively. The PFS for patients with AML in complete
remission 1 or 2 was 36% (95% CI, 11% to 63%) (Table 2).Table 4
Outcomes of Matched Cohort Analysis: Post-CY versus Tacrolimus/MTX
Outcome HR (95% CI) P Value
Follow-up, median (range), mo
Post-CY 37 (24-43)
Tacrolimus/MTX 20 (12-63)
Acute GVHD II to IV
Post-CY 46% (32-65) 2.8 (1.1-6.8) .02
Tacrolimus/MTX 19% (10-37) Ref.
Acute GVHD III to IV
Post-CY 14% (6-32) N/E .02
Tacrolimus/MTX 0% (2-70)
Chronic GVHD at 1 year
Post-CY 20% (10-39) 1.0 (.4-2.8) .90
Tacrolimus/MTX 22% (12-40) Ref.
Day 100 TRM
Post-CY 11% (4-27) 2.1 (.4-11.6) .40
Tacrolimus/MTX 5% (1-21) Ref.
2-Year TRM
Post-CY 35% (23-54) 3.3 (1.1-8.5) .035
Tacrolimus/MTX 13% (6-30) Ref.
Day 100 CMV-reactivation
Post-CY 1.3 (.6-2.6) .50
Tacrolimus/MTX Ref.
Progression at 2 years
Post-CY 35% (23-54) .9 (.4-1.9) .80
Tacrolimus/MTX 44% (30-63) Ref.
PFS at 2 years
Post-CY 22% (10-36) 1.6 (.9-2.8) .10
Tacrolimus/MTX 43% (27-58) Ref.
OS at 2 years
Post-CY 30% (16-45) 1.9 (1.02-3.2) .04
Tacrolimus/MTX 52% (35-67) Ref.Results of Matched Control Analysis
A total of 133 patients received a RIC regimenwith standard
GVHD prophylaxis of tacrolimus and mini-dose MTX over the
study period. Comparison of outcomes between this un-
matched cohort and the patients enrolled onto the phase II trial
with post-CY was performed prior to performing the matched
cohort analysis. There was an increased risk of grades II to IV
and III and IV acute GVHD and trends for worst NRM and OS in
those who received post-CY (Supplemental Table 2).
Matchingwas then performed, inwhichmatched controls
were successfully identiﬁed for 37 of the 49 patients enrolled
onto the protocol, based on the matching algorithm detailed
in the Methods section. The exclusion of ATG in a portion of
the MUD recipients enrolled onto the study resulted in the
inability to identify a historical match in 11 of the 12 un-
matched cases. The patient characteristics for the remaining
37 enrolled patients and 37 matched controls are shown in
Table 2, with the 2 groups having similar characteristics with
the exception that PB grafts were more common in MRD
transplantation patients receiving tacrolimus/MTX (14 of 15
patients) versus post-CY (9 of 15 patients). Among the
matched controls, the cumulative incidence of grade II to IV
acute GVHD was comparable for recipients of RIC with the
Bu/Flu and Flu/melphalan regimens (20% versus 18%; HR,1.2;
P ¼ .8, 95% CI, .3% to 5.3%). Furthermore, within the matched,
control group, BuFlu and Flu/melphalan conditioning resul-
ted in statistically comparable rates of PFS, progression, TRM,
acute GVHD III and IV, and chronic GVHD, justifying the use
of both conditioning regimens within the matched control
cohort (Supplemental Table 3).The incidences of grade II to IV and III to IV acute GVHD
were signiﬁcantly higher in recipients of Post-CY when
compared with matched patients who received a tacrolimus/
MTX prophylaxis (grade II to IV 46% versus 19%; HR, 2.8;
P ¼ .02, 95% CI, 1.1 to 6.8). This resulted in higher TRM at
2 years after transplantation (HR, 3.3; 95% CI, 1.1 to 8.5;
P ¼ .035) and worse OS (HR, 1.9; 95% CI, 1.02 to 3.5; P ¼ .04)
for patients receiving Post-CY (Table 4, Figure 1). The cu-
mulative incidence of chronic GVHD and the rate of CMV
reactivation did not differ, whereas the median times to
neutrophil and platelet engraftment were statistically higher
in patients who received Post-CY compared with matched-
controls.
DISCUSSION
Improvement in GVHD prophylaxis can be realized by
either a reduction in the incidence and severity of acute
GVHD or a reduction in complications associated with
immunosuppressive therapy. Ultimately, the goal is to ach-
ieve long-term disease-free survival with full immune
reconstitution without acute or chronic GVHD. Risks for
GVHD-related complications may differ based on patients
factors, such as age and sex match, as well as treatment-
related factors including conditioning regimen, donor-type
and graft source. In this trial, we sought to determine
whether post-CY would be effective in patients receiving RIC
and have any advantages compared to the use of standard
CNI-based GVHD prophylaxis. We found that in the RIC
setting, the post-CY regimen was associated with higher
rates of acute GVHD and TRM and inferior PFS and OS,
compared with matched controls.
The results of this phase II trial have furthered our
knowledge of Post-CY GVHD prophylaxis in many important
ways. First, the patient population and the intensity of the
conditioning regimen may be important. Although original
Figure 1. Comparison of Acute GVHD II to IV (A), acute GVHD III/IV (B), nonrelapse mortality (C), relapse (D) and overall survival (E) in recipients of GVHD prophylaxis
with Post-CY (dashed line) and tacrolimus/methotrexate (solid line) after RIC allogeneic transplantations from MRD and MUDs.
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similar rates of acute GVHD as CNI-based prophylaxis in
patients receiving myeloablative conditioning [6], results of
our matched cohort analysis suggest that Post-CY is less
effective in the RIC setting involving older or medically
inﬁrm patients. The rate of grade II to IV acute GVHD was
more than 2-fold higher when compared to patients who
received CNI-based prophylaxis. Higher rates of acute GVHD
resulted in worse TRM and OS with no associated improve-
ment in rates of progression in this patient population. Better
than expected outcomes in our matched control cohort mayhave accounted for the inferior results seenwith the post-CY
group; however, we feel this is unlikely to be the case. First,
an unmatched analysis (using the total 133 controls)
demonstrated consistent results as those obtained in the
matched analysis (Supplemental Table 2). Second, the rate of
acute GVHD seen in our control group is similar to the pub-
lished rates seen in a recent multicenter trial that employed a
similar conditioning regimen and CNI/MTX in older-aged
patients with AML (NCT00070135) [17], a recent study by
Alyea et al., and published studies from our institution
[18,19].
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not see a reduction in the rate of chronic GVHD with the
post-CY regimen. It is possible that the high rate of acute
GVHD and/or the resultant need for initiation of a CNI may
have negated the apparent protection from chronic GVHD,
which has been previously reported with the CNI-free, post-
CY prophylaxis regimen [2-6]. Additionally, the predominant
use of BM grafts in the earlier reports may account for the
lower rates of chronic GVHD.
Two additional areas of debate with respect to GVHD
prevention include the use of ATG and BM versus PB pro-
genitor cells as the graft source. Registry data from Soiffer
et al. suggest that the use of ATG may have detrimental
overall effect when RIC is employed [20]. Although the use of
ATG in a subset of MUD recipients may be one explanation
for differences in our outcomes when compared to the
original reports of Post-CY [6], we think this is unlikely to be
the case. A comparison of outcomes for MUD recipients with
or without receipt of ATG found that the use of ATG resulted
in a statistically lower (not higher) rate of acute GVHD
(Table 3). It is possible that ATGmay have negatively affected
progression and OS, as suggested by Soiffer et al., but our
numbers are too small to allow for an analysis accounting for
disease type and remission status to examine this question.
Thus, the role of ATG with post-CY GVHD prophylaxis should
be further evaluated. Additionally, BM was the sole graft
source for patients in the original Post-CYpublication [6]. We
sought to determine whether PB could also be employed
with Post-CY. PB remains the most common graft source
used for MRD transplantations, making it important to
determine if this source can be employed with the post-CY
strategy. Our data showed a trend toward a higher rate of
acute GVHD grade II to IV after PB transplantations; however,
this did not reach statistical signiﬁcance in this relatively
small study. These results suggest caution should be used
when using PB grafts with post-CY.
The question remains why outcomes were worse for re-
cipients of Post-CY after RIC with Bu/Flu when compared to
matched controls who received a CNI/MTX prophylactic
regimen. First, it is important to note that this observation
was seen with the Bu/Flu RIC regimen, and although the
impact of post-CY on other RIC regimens can be inferred, it
cannot be deﬁnitively concluded. It is possible that a more
ablative regimen is needed to result in signiﬁcant allo-
reactivity at the time of infusion of CY on days þ3 and þ4.
However, recent work has suggested Post-CY may not work
through ablation of alloreactive T cells (as originally sug-
gested in mouse models) but through preferential sparing of
suppressive T cells (regulatory T cells) [7]. If this is true, it is
unclear why a reduction in conditioning intensity would be
detrimental to this proposed mechanism.
A multicenter trial by Kanakry evaluating GVHD prophy-
laxis with post-CY after myeloablative conditioning with Bu
(targeting an area under the curve of roughly 5000
micromolar-minute) and Flu has recently been reported [9].
It should be noted that the rates of grade II to IV aGVHD
(51%), grade III to IV aGVHD (15%), and chronic GVHD (14%)
reported in the Kanakry trial were comparable to the rates of
GVHD in our trial of 53%, 22%, and 18%, respectively. In
contrast, an impressive PFS and OS of 62% and 67% at 2 years
was seen in the Kanakry publication compared with PFS and
OS in our study of 26% and 33%, respectively, at 2 years, likely
reﬂecting differences in the patient populations in each
study. The Kanakry study, involved a younger population,
with median age of 49 years, ﬁt for a myeloablative regimen(hematopoietic cell transplantationespeciﬁc comorbidity
index was not reported). Our cohort of patients were older,
with median age of 62 years, and had a high rate of comor-
bidities (median hematopoietic cell transplantationespeciﬁc
comorbidity index of 3), necessitating only a RIC regimen.
The rates of relapse were slightly lower in the Kanakry study
(cumulative incidence relapse 22% versus 26% in our study),
but the TRMwas signiﬁcantly higher in our study (31% versus
16%), suggesting that older patients and/or those with a
number of comorbidities may be more impacted by acute
GVHD when it occurs. A study by Sorror et al. demonstrated
increased rates of TRM with acute GVHD in older patients
and those with a higher comorbidity index [21,22]. Our
analysis indicates that GVHD prophylaxis with post-CY re-
sults in higher rates of acute GVHD grades II-IV and III/IV
when compared to traditional prophylaxis with a CNI/MTX.
The degree to which these higher rates for acute GVHD
translate into higher TRM is further inﬂuenced by the pop-
ulation being studied; differing study populations between
our study population and those of other reports of post-CY
likely account for the marked differences with respect to
TRM and OS despite comparable rates of GVHD.
The Blood and Marrow Transplant Clinical Trials Network
will be conducting a 3-arm study of novel GVHD prophylaxis
strategies after RIC, T cellereplete, matched donor trans-
plantations. Because of concerns with the use of Post-CY
prophylaxis in the RIC setting, one treatment arm will test
post-CY combined with a CNI and mycophenolate mofetil, a
strategy that has been shown to be successful in RIC and
nonmyeloablative haploidentical hematopoietic trans-
plantation [23,24].
In conclusion, use of post-CY has been proposed as a CNI-
free regimen that could avoid ongoing post-transplantation
immunosuppressive therapy. In a matched control analysis,
we found that post-CY, when combined with RIC, was infe-
rior compared with matched controls receiving tacrolimus-
MTX for prevention of grades II to IV and III and IV acute
GVHD, resulting in poorer TRM and OS. Our trial suggests
that traditional GVHD prophylaxis with a CNI/MTX should be
employed rather than post-CY when performing RIC trans-
plantation from a HLA- matched related or unrelated donor.
Post-CY combined with a CNI/mycophenolate mofetil will be
studied as alternative strategy in an upcoming Blood and
Marrow Transplant Clinical Trials Network trial.ACKNOWLEDGMENTS
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